Paul Beastall
Paul is the nominated Director for Innovate UK on the Board of Medicines Discovery Catapult and was appointed in 2022. He is an engineer who has spent his career working at the interface between technical innovation and successful business, working with organisations from multinational corporations to venture-funded start-ups. Prior to moving to build a portfolio career, […]
Professor Chris Molloy
Professor Chris Molloy has a 30-year international board and executive career across a unique range of life sciences R&D disciplines. His career began in preclinical research at Glaxo, where he was closely involved with the industrialisation of high throughput discovery. In 2004 he moved to Asia as COO of MerLion Pharmaceuticals, a Singaporean biotech that […]
Robert Sherville-Payne
With a professional legal and compliance background and over 25 years of commercial experience, Robert brings significant expertise as a solicitor to his role as General Counsel and Company Secretary at Medicines Discovery Catapult. Having trained and worked at law firm Hogan Lovells in London, Robert spent 14 years at AstraZeneca in a range of […]
Dr Emily Offer
Emily has 20 years’ experience in cell and molecular biology applied to drug discovery. Emily’s academic research involved the development and validation of stem cell derived models of disease and has subsequently led teams in large global pharma and biotech companies, developing cellular assays for both screening and phenotypic analysis of large and small molecule […]
Dr Tatiane Takahashi
Tatiane has over 11 years of pre-clinical research experience within academia and industry. She has expertise in psychiatric disorders and oncology, as well as experience in leading in vivo drug discovery projects of complex medicines. Tatiane is well acquainted in applying non-destructive imaging modalities in in vivo studies, such as PET, CT, MRI and IVIS, […]
Dr Sally-Ann Emmas
Sally-Ann is a highly experienced scientist and project leader with over 25 years of experience in Research and Development. Her expertise covers diagnostic and pharmaceutical fields, with experience in pre-clinical and clinical development across different disciplines, with a focus on translational research. Following a PhD in surgical research, Sally-Ann joined GE Healthcare in 1999 as […]
Dr Irma Berrueta Razo
Irma completed a PhD at the University of Manchester studying molecular imaging on mouse brain samples using the TOF-SIMS technique. Prior to joining MDC, Irma worked as a post-doctoral researcher at the University of Manchester. During this time, Irma developed methods for applying Mass Spectrometry Imaging (MSI) to a range of samples using cutting-edge techniques to answer biological questions. Irma has experience with imaging biological tissues using techniques […]
Dr Kerry Shea
Graduating with a BSc in Biochemistry from the University of Sheffield, Kerry completed an AstraZeneca-funded Ph.D. from the Randall Centre for Cell and Molecular Biophysics at King’s College London, examining protein/protein interactions during cell migration. Subsequently moving into industry, she has worked in large pharma, small biotech and CRO organisations and has significant experience in […]
Dr Bruno Bellina
Dr Bruno Bellina obtained his PhD in Molecular Spectroscopy from the University Claude Bernard Lyon 1. He then moved for a year to the University of Southern California, Los Angeles (US) where he worked as a post-doctoral researcher in Molecular Physics. Following this, he joined the institute of biotechnology in Manchester (UK), as a post-doctoral […]